SCHEDULE 13G/A: Capital International Investors Discloses 9.3% Stake in Sarepta Therapeutics

Capital International Investors has filed an amended Schedule 13G, revealing a beneficial ownership of 9.3% in Sarepta Therapeutics, Inc. as of December 31, 2024.

Summary

• Capital International Investors (CII) reported beneficial ownership of 8,896,223 shares of Sarepta Therapeutics, Inc. common stock.
• This stake represents 9.3% of the total 95,519,650 shares believed to be outstanding.
• CII holds sole voting power over 8,879,638 shares and sole dispositive power over 8,896,223 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported position.
• The event requiring this filing occurred on December 31, 2024, with the filing signed on February 13, 2025.

Sentiment

Score: 7

Explanation: Capital International Investors, a major institutional investor, has disclosed a significant 9.3% beneficial ownership in Sarepta Therapeutics, Inc., which can be interpreted as a vote of confidence in the company's future.

Positives

• A significant stake of 9.3% held by a major institutional investor like Capital International Investors may signal confidence in Sarepta Therapeutics, Inc.'s long-term prospects.
• The continued holding of a substantial position by Capital International Investors suggests a stable institutional investor base for Sarepta Therapeutics.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Capital International Investors may instill confidence among existing shareholders and attract new investors, potentially influencing stock valuation positively.

Key Dates

Keywords

Sarepta Therapeutics, Capital International Investors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing